AstraZeneca PLC (LON:0A4J)

London flag London · Delayed Price · Currency is GBP · Price in USD
70.92
-0.38 (-0.53%)
At close: Jan 31, 2025
5.50%
Market Cap 181.54B
Revenue (ttm) 43.19B
Net Income (ttm) 5.62B
Shares Out n/a
EPS (ttm) 3.59
PE Ratio 32.31
Forward PE n/a
Dividend 1.20 (1.69%)
Ex-Dividend Date Feb 21, 2025
Volume 11,721
Average Volume 10,706
Open 70.69
Previous Close 71.30
Day's Range 70.48 - 71.51
52-Week Range 60.48 - 87.62
Beta 0.20
RSI 67.48
Earnings Date Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]

Industry Pharmaceutical Preparations
Founded 1992
Employees 89,900
Stock Exchange London Stock Exchange
Ticker Symbol 0A4J
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

There is no news available yet.